Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Jan, Lycke"'
Autor:
Lenka Novakova, Anna Karin Hedström, Markus Axelsson, Anne Frandsen Brandt, Lars Alfredsson, Tomas Olsson, Jan Lycke
Publikováno v:
Brain and Behavior, Vol 14, Iss 3, Pp n/a-n/a (2024)
Abstract Background A significant proportion of individuals with suspicious onset of multiple sclerosis (MS) does not fulfill the diagnostic criteria. Although some receive other diagnoses, many remain undiagnosed and lack healthcare follow‐up. Thi
Externí odkaz:
https://doaj.org/article/fc59ed666d324f91830d1944a59b9bee
Autor:
Mark S. Freedman, Sharmilee Gnanapavan, Ronald A. Booth, Peter A. Calabresi, Michael Khalil, Jens Kuhle, Jan Lycke, Tomas Olsson
Publikováno v:
EBioMedicine, Vol 101, Iss , Pp 104970- (2024)
Summary: Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There is now substantial evidence for this biomarker to be
Externí odkaz:
https://doaj.org/article/4e3c083cc88e45e594ebc2a3e2e3dc56
Autor:
Sofia Sandgren, Lenka Novakova, Anna Nordin, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundAlemtuzumab (ALZ) is a pulsed immune reconstitution therapy for multiple sclerosis (MS).ObjectiveTo assess basic characteristics, therapeutic effects, and prognostic biomarkers on clinical and imaging parameters of disease activity for rela
Externí odkaz:
https://doaj.org/article/1a51aa49d87b4da59edc2051d2fd6490
Autor:
Elisa Longinetti, Hannah Bower, Kyla A McKay, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell‐Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer‐Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergård, Tomas Olsson, Fredrik Piehl, Thomas Frisell
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 9, Iss 9, Pp 1449-1458 (2022)
Abstract Objective To estimate risks for all‐cause mortality and for severe COVID‐19 in multiple sclerosis patients and across relapsing–remitting multiple sclerosis patients exposed to disease‐modifying therapies. Methods We conducted a Swed
Externí odkaz:
https://doaj.org/article/f5e46de376404433ae57cd4c2d571b4d
Autor:
Magnus Johnsson, Fredrik Asztely, Susanne Hejnebo, Markus Axelsson, Clas Malmeström, Torbjörn Olausson, Jan Lycke
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 9, Iss 8, Pp 1296-1301 (2022)
Abstract SARS‐COV‐2 frequently cause neurological disorders and is sometimes associated with onset of autoimmune diseases affecting the nervous system. Over recent years, a rare but distinct diagnosis designated myelin oligodendrocyte glycoprotei
Externí odkaz:
https://doaj.org/article/7ac733ed610b493fae51ca6944200cbe
Autor:
Sofia Sandgren, Lenka Novakova, Markus Axelsson, Firoozeh Amirbeagi, Ingrid Kockum, Tomas Olsson, Clas Malmestrom, Jan Lycke
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundAlemtuzumab (ALZ) is an immune reconstitution therapy for treating relapsing-remitting multiple sclerosis (RRMS). However, ALZ increases the risk of secondary autoimmune diseases (SADs).ObjectiveWe explored whether the detection of autoimmu
Externí odkaz:
https://doaj.org/article/57d02a89c1f745458ba0c6a29dfd6ed3
Autor:
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Sofia Rasch, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundEvolving evidence suggests that measurement of cerebrospinal fluid (CSF) kappa free light chain (KFLC) synthesis has high diagnostic sensitivity and specificity for multiple sclerosis (MS), but its prognostic ability is less investigated. T
Externí odkaz:
https://doaj.org/article/22580cb307b44a869eff8346adbec0e9
Autor:
Igal Rosenstein, Sofia Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundEmerging evidence supports that determination of intrathecal immunoglobulin M (IgM) synthesis (ITMS) and neurofilament light (NfL) concentration in cerebrospinal fluid (CSF) may be clinically useful as disease severity biomarkers in relapsi
Externí odkaz:
https://doaj.org/article/b3805a9ddeac443699809381360d79eb
Autor:
Nicholas J. Ashton, Shorena Janelidze, Ahmad Al Khleifat, Antoine Leuzy, Emma L. van der Ende, Thomas K. Karikari, Andrea L. Benedet, Tharick A. Pascoal, Alberto Lleó, Lucilla Parnetti, Daniela Galimberti, Laura Bonanni, Andrea Pilotto, Alessandro Padovani, Jan Lycke, Lenka Novakova, Markus Axelsson, Latha Velayudhan, Gil D. Rabinovici, Bruce Miller, Carmine Pariante, Naghmeh Nikkheslat, Susan M. Resnick, Madhav Thambisetty, Michael Schöll, Gorka Fernández-Eulate, Francisco J. Gil-Bea, Adolfo López de Munain, Ammar Al-Chalabi, Pedro Rosa-Neto, Andre Strydom, Per Svenningsson, Erik Stomrud, Alexander Santillo, Dag Aarsland, John C. van Swieten, Sebastian Palmqvist, Henrik Zetterberg, Kaj Blennow, Abdul Hye, Oskar Hansson
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Cerebrospinal fluid neurofilament light (NfL) is a biomarker for neurodegeneration that can also be assessed in blood. Here the authors show in a validation study the potential for plasma NfL as a biomarker for several neurodegenerative diseases.
Externí odkaz:
https://doaj.org/article/5a53b0a732414b4ca05246e46c25baa3
Autor:
Raymond Hupperts, Claudio Gasperini, Jan Lycke, Tjalf Ziemssen, Peter Feys, Shan Xiao, Carlos Acosta, Thijs Koster, Jeremy Hobart
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 15 (2022)
Background: MOBILE and ENHANCE were similarly designed randomized trials of walking-impaired adults with relapsing-remitting or progressive multiple sclerosis (MS) who received placebo or 10 mg prolonged-release (PR)-fampridine twice daily for 24 wee
Externí odkaz:
https://doaj.org/article/03fc17d5dd044fea88adf019de1daacf